Manila Times Business
Rivus Pharmaceuticals Announces Preclinical Data for RV-8451, a Muscle-Preserving, Oral GLP-1, at ADA 2026 Scientific Sessions
- Preclinical NHP data demonstrate significant fat‑specific weight loss with RV‑8451, while preserving lean mass and showing no gastrointestinal adverse events - - IND‑enabling studies advancing, with IND submission for RV-8451 in obesity targeted for Q1 2027 - - Greater fat loss in head-to-head NHP study versus orforglipron while preserving lean mass - CHARLOTTESVILLE, Va., and SOUTH SAN FRANCISCO, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Rivus Pharmaceuticals, Inc., a clinical-stage biopharma
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Granite Credit Union Invites Community to Celebrate Eagle Mountain Grand Opening
Just now
E.F. Hutton & Co. Will Serve as Platinum Sponsor at The SPAC Conference 2026
Just now
Family questions rescue efforts for Sherpa guide found alive on Everest
Just now
Gunmen kidnap 7 students from school in northwestern Nigeria
Just now